阳性微生物学检测对社区获得性肺炎抗菌药物降阶梯及结局的影响:倾向性评分分析
该研究基于前瞻性收集的队列进行回顾性分析,纳入3677例非免疫抑制的社区获得性肺炎(CAP)住院成人。1924例(52.3%)微生物学检测阳性者中33.7%实施抗菌药物降阶梯,而1753例阴性者中仅10.2%实施降阶梯。阳性检测与降阶梯独立相关(AOR 2.59;95%CI 1.96-3.41),且降阶梯未增加30天病死率、不良事件或CAP复发风险。
要点
- CAP住院患者中微生物学检测阳性者抗菌药物降阶梯比例(33.7%)高于阴性者(10.2%)。
- 阳性微生物学检测与降阶梯独立相关(AOR 2.59;95%CI 1.96-3.41)。
- 降阶梯未增加30天病死率(AHR 0.44;95%CI 0.14-1.43)、不良事件或CAP复发风险。
核心结论
- 在CAP住院患者中,微生物学检测阳性者较阴性者更常实施抗菌药物降阶梯,且降阶梯未对相关临床结局产生不利影响。
研究设计与样本
- 对前瞻性收集的CAP住院非免疫抑制成人队列进行回顾性分析,共纳入3677例患者。
主要发现
- 1924/3677例(52.3%)微生物学检测阳性,其中648/1924例(33.7%)实施降阶梯;阴性者中179/1753例(10.2%)实施降阶梯。
- 多因素分析中,阳性微生物学检测(AOR 2.59;95%CI 1.96-3.41)和第3天临床稳定性(AOR 1.87;95%CI 1.45-2.10)是与降阶梯独立相关的主要因素。
- 校正病因特异Cox模型后,降阶梯与30天病死率(AHR 0.44;95%CI 0.14-1.43)、不良事件(AHR 0.77;95%CI 0.53-1.12)或CAP复发(AHR 0.65;95%CI 0.35-1.14)无显著关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The usefulness of routine microbiological testing for rationalising antibiotic use in hospitalised patients with community-acquired pneumonia (CAP) continues to be a subject of debate. We aim to determine the effect of positive microbiological testing on antimicrobial de-escalation and clinical outcomes in CAP. METHODS: A retrospective analysis of a prospectively collected cohort of non-immunosuppressed adults hospitalised with CAP was performed. The primary study outcome was antimicrobial de-escalation. Secondary outcomes included 30-day case-fatality rate, adverse events, and CAP recurrence. Adjustment for confounders was performed by inverse probability weighting propensity score, logistic regression, and cause-specific Cox model. RESULTS: Of 3677 patients with CAP, 1924 (52.3%) had any positive microbiological test. Antimicrobial de-escalation was performed in 648/1924 (33.7%) of patients with positive microbiological testing and in 179/1753 (10.2%) of those with non-positive results. When propensity score was entered into the multivariate analysis, positive microbiological testing (adjusted OR (AOR)], 2.59; 1.96-3.41) and clinical stability at day 3 (AOR 1.87; 1.45-2.10) were two of the main factors independently associated with antimicrobial de-escalation. After applying an adjusted cause-specific Cox model, antimicrobial de-escalation was not associated with a higher 30-day case-fatality rate (adjusted hazard ratio (AHR), 0.44 (95% CI, 0.14-1.43)), higher frequency of adverse events (AHR, 0.77 (95% CI, 0.53-1.12)), or CAP recurrence (AHR, 0.65 (95% CI, 0.35-1.14)). DISCUSSION: Antimicrobial de-escalation was more often performed in hospitalised patients with CAP who had positive microbiological tests than in those with non-positive results, and it did not adversely affect relevant clinical outcomes.
引用
- Abelenda-Alonso G, Rombauts A, Gudiol C, et al. Effect of positive microbiological testing on antibiotic de-escalation and outcomes in community-acquired pneumonia: a propensity score analysis. Clin Microbiol Infect. 2022. PMID: 35809784. doi:10.1016/j.cmi.2022.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。